LONDON, November 29, 2016 /PRNewswire/ -- We are initiating coverage on Quantum Genomics, a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure with a completed and an ongoing Phase IIa study, respectively. This pathway has been implicated in patients with complicated hypertension including those who are resistant to other treatments (25%) and 52% of hypertensive African Americans. We initiate with a valuation of €172m. (Logo: http://photos.prnewswire.com/prnh/20130417/608168 ) We value Quantum Genomics at €172m or €20.51/share based on a risk-adjusted NPV. We value the two programmes at €79m and €80m, although this represents higher revenue potential ( $2.1bn vs $1.3bn peak sales) and higher development cost for hypertension. We forecast that the company will require €20m in financing before it can out-license the programmes in 2019 after completing Phase IIb studies. Click here to view the full report. All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com. About Edison: Edison is an international equity research firm with a team of over 70 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.